Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers

Get an expert&rsquo s take on the evolving role of immune checkpoint inhibitors in managing advanced gastric and esophageal cancers with this program which features a series of ClinicalThought&trade commentaries on emerging clinical data managing immune-related adverse events and key biomarkers of response.

Share

Program Content

Activities

ICIs for Gastroesophageal Cancers
Immune Checkpoint Inhibitors for Advanced Gastroesophageal Cancers: Key Findings From ASCO GI 2019
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2019

Expires: February 25, 2020

irAEs in Gastric-GEJ
Identifying and Managing Immune-Related Adverse Events in Patients With Advanced Gastroesophageal Cancers Receiving Checkpoint Inhibitors
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2019

Expires: March 20, 2020

ICIs in Gastric/GEJ
How I Use Checkpoint Inhibitors in Later-line Advanced Gastric/GEJ Cancers
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 18, 2019

Expires: July 16, 2020

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb